{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T20:35:37Z","timestamp":1793046937820,"version":"4.5.0"},"reference-count":33,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2021,12,1]],"date-time":"2021-12-01T00:00:00Z","timestamp":1638316800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"},{"start":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T00:00:00Z","timestamp":1639008000000},"content-version":"vor","delay-in-days":8,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0"}],"funder":[{"DOI":"10.13039\/501100003593","name":"conselho nacional de desenvolvimento cient\u00edfico e tecnol\u00f3gico","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100003593","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100006507","name":"funda\u00e7\u00e3o oswaldo cruz","doi-asserted-by":"publisher","id":[{"id":"10.13039\/501100006507","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Parasites Vectors"],"published-print":{"date-parts":[[2021,12]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:sec><jats:title>Background<\/jats:title><jats:p><jats:italic>Leishmania infantum<\/jats:italic>is the most important etiological agent of visceral leishmaniasis in the Americas and Mediterranean region, and the dog is the main host. Miltefosine was authorized to treat canine leishmaniasis (CanL) in Brazil in 2017, but there is a persistent fear of the emergence of parasites resistant not only to this drug but, through cross-resistance mechanisms, also to meglumine antimoniate and amphotericin B. Additionally, the literature shows that acquisition of resistance is followed by increased parasite fitness, with higher rates of proliferation, infectivity and metacyclogenesis, which are drivers of parasite virulence. In this context, the aim of this study was to analyze the impact of treating a dog with miltefosine and allopurinol on the generation of parasites resistant to miltefosine, amphotericin B and meglumine antimoniate.<\/jats:p><\/jats:sec><jats:sec><jats:title>Methods<\/jats:title><jats:p>In vitro susceptibility tests were conducted against miltefosine, amphotericin B and meglumine antimoniate with T0 (parasites isolated from a dog before treatment with miltefosine plus allopurinol), T1 (after 1 course of treatment) and T2 (after 2 courses of treatment) isolates. The rates of cell proliferation, infectivity and metacyclogenesis of the isolates were also evaluated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Results<\/jats:title><jats:p>The results indicate a gradual increase in parasite resistance to miltefosine and amphotericin B with increasing the number of treatment courses. An increasing trend in the metacyclogenesis rate of the parasites was also observed as drug resistance increased.<\/jats:p><\/jats:sec><jats:sec><jats:title>Conclusion<\/jats:title><jats:p>The data indicates an increased<jats:italic>L. infantum<\/jats:italic>resistance to miltefosine and amphotericin B after the treatment of a dog with miltefosine plus allopurinol. Further studies with a larger number of<jats:italic>L. infantum<\/jats:italic>strains isolated from dogs with varied immune response profiles and undergoing different treatment regimes, are advocated.<\/jats:p><\/jats:sec><jats:sec><jats:title>Graphical Abstract<\/jats:title><\/jats:sec>","DOI":"10.1186\/s13071-021-05100-x","type":"journal-article","created":{"date-parts":[[2021,12,9]],"date-time":"2021-12-09T10:04:28Z","timestamp":1639044268000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":29,"title":["Increased Leishmania infantum resistance to miltefosine and amphotericin B after treatment of a dog with miltefosine and allopurinol"],"prefix":"10.1186","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-4670-9256","authenticated-orcid":false,"given":"Gustavo","family":"Gon\u00e7alves","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Monique Paiva","family":"Campos","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Alessandra Silva","family":"Gon\u00e7alves","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lia Carolina Soares","family":"Medeiros","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Fabiano Borges","family":"Figueiredo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2021,12,9]]},"reference":[{"issue":"Suppl 1","key":"5100_CR1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1186\/1756-3305-2-S1-S1","volume":"2","author":"F Dantas-Torres","year":"2009","unstructured":"Dantas-Torres F. Canine leishmaniosis in South America. Parasit Vectors. 2009;2(Suppl 1):S1.","journal-title":"Parasit Vectors"},{"key":"5100_CR2","unstructured":"Departamento de vigil\u00e2ncia epidemiol\u00f3gica, Secretaria de Vigil\u00e2ncia em Sa\u00fade, Minist\u00e9rio da Sa\u00fade (BR). Guia de Vigil\u00e2ncia em Sa\u00fade. 3rd ed. Brasilia: Minist\u00e9rio da Sa\u00fade (BR). 2019."},{"key":"5100_CR3","doi-asserted-by":"publisher","first-page":"851","DOI":"10.1590\/S0034-8910.2014048005615","volume":"48","author":"GL Werneck","year":"2014","unstructured":"Werneck GL. Visceral leishmaniasis in Brazil: rationale and concerns related to reservoir control. Rev Saude Publica. 2014;48:851\u20135.","journal-title":"Rev Saude Publica"},{"key":"5100_CR4","unstructured":"Minist\u00e9rio da Agricultura, Pecu\u00e1ria e Abastecimento e Minist\u00e9rio da Sa\u00fade. Nota t\u00e9cnica conjunta no. 001\/2016. https:\/\/www.sbmt.org.br\/portal\/wp-content\/uploads\/2016\/09\/nota-tecnica.pdf. Accessed 18 Sep 2021."},{"key":"5100_CR5","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1186\/s13071-019-3323-0","volume":"12","author":"NF dos Santos","year":"2019","unstructured":"dos Santos NF, Avino VC, Galvis-Ovallos F, Pereira-Chioccola VL, Moreira MAB, Romariz APPL, et al. Use of miltefosine to treat canine visceral leishmaniasis caused by Leishmania infantum in Brazil. Parasit Vectors. 2019;12:79.","journal-title":"Parasit Vectors"},{"key":"5100_CR6","doi-asserted-by":"publisher","first-page":"289","DOI":"10.1186\/s13071-015-0896-0","volume":"8","author":"L Manna","year":"2015","unstructured":"Manna L, Corso R, Galiero G, Cerrone A, Muzj P, Gravino AE. Long-term follow-up of dogs with leishmaniosis treated with meglumine antimoniate plus allopurinol versus miltefosine plus allopurinol. Parasit Vectors. 2015;8:289.","journal-title":"Parasit Vectors"},{"key":"5100_CR7","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1016\/j.vetpar.2011.05.009","volume":"181","author":"HM Andrade","year":"2011","unstructured":"Andrade HM, Toledo VPCP, Pinheiro MB, Guimar\u00e3es TMPD, Oliveira NC, Castro JA, et al. Evaluation of miltefosine for the treatment of dogs naturally infected with L. infantum (=L. chagasi) in Brazil. Vet Parasitol. 2011;181:83\u201390.","journal-title":"Vet Parasitol"},{"key":"5100_CR8","doi-asserted-by":"publisher","first-page":"873","DOI":"10.1038\/nrmicro1748","volume":"5","author":"F Chappuis","year":"2007","unstructured":"Chappuis F, Sundar S, Hailu A, Ghalib H, Rijal S, Peeling RW, et al. Visceral leishmaniasis: what are the needs for diagnosis, treatment and control? Nat Rev Microbiol. 2007;5:873\u201382.","journal-title":"Nat Rev Microbiol"},{"key":"5100_CR9","doi-asserted-by":"publisher","first-page":"3097","DOI":"10.1128\/AAC.42.12.3097","volume":"42","author":"D Sereno","year":"1998","unstructured":"Sereno D, Cavaleyra M, Zemzoumi K, Maquaire S, Ouaissi A. Axenically grown amastigotes of Leishmania infantum used as an in vitro model to investigate the pentavalent antimony mode of action. Antimicrob Agents Chemother. 1998;42:3097\u2013102.","journal-title":"Antimicrob Agents Chemother"},{"key":"5100_CR10","doi-asserted-by":"publisher","first-page":"835","DOI":"10.1128\/AAC.01233-08","volume":"53","author":"D Kumar","year":"2009","unstructured":"Kumar D, Kulshrestha A, Singh R, Salotra P. In vitro susceptibility of field isolates of Leishmania donovani to miltefosine and amphotericin B: correlation with sodium antimony gluconate susceptibility and implications for treatment in areas of endemicity. Antimicrob Agents Chemother. 2009;53:835\u20138.","journal-title":"Antimicrob Agents Chemother"},{"key":"5100_CR11","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1093\/jac\/dky450","volume":"74","author":"E Eberhardt","year":"2019","unstructured":"Eberhardt E, Bult\u00e9 D, van Bockstal L, van den Kerkhof M, Cos P, Delputte P, et al. Miltefosine enhances the fitness of a non-virulent drug-resistant Leishmania infantum strain. J Antimicrob Chemother. 2019;74:395\u2013406.","journal-title":"J Antimicrob Chemother"},{"key":"5100_CR12","doi-asserted-by":"publisher","first-page":"e0005641","DOI":"10.1371\/journal.pntd.0005641","volume":"11","author":"DK Deep","year":"2017","unstructured":"Deep DK, Singh R, Bhandari V, Verma A, Sharma V, Wajid S, et al. Increased miltefosine tolerance in clinical isolates of Leishmania donovani is associated with reduced drug accumulation, increased infectivity and resistance to oxidative stress. PLoS Negl Trop Dis. 2017;11:e0005641.","journal-title":"PLoS Negl Trop Dis"},{"key":"5100_CR13","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1128\/mBio.00611-13","volume":"4","author":"K Rai","year":"2013","unstructured":"Rai K, Cuypers B, Bhattarai NR, Uranw S, Berg M, Ostyn B, et al. Relapse after treatment with miltefosine for visceral leishmaniasis is associated with increased infectivity of the infecting Leishmania donovani strain. MBio. 2013;4:11\u20133.","journal-title":"MBio"},{"key":"5100_CR14","doi-asserted-by":"publisher","first-page":"2802","DOI":"10.1128\/iai.55.11.2802-2806.1987","volume":"55","author":"R da Silva","year":"1987","unstructured":"da Silva R, Sacks LD. Metacyclogenesis is a major determinant of Leishmania promastigote virulence and attenuation. Infect Immun. 1987;55:2802\u20136.","journal-title":"Infect Immun"},{"key":"5100_CR15","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1590\/S1678-9946201658003","volume":"58","author":"TR Abrantes","year":"2016","unstructured":"Abrantes TR, de Madeira MF, da Silva DA, dos Carolina Peri\u00e9 SFS, Mendes Junior AA, Menezes RC, et al. Identification of canine visceral leishmaniasis in a previously unaffected area by conventional diagnostic techniques and cell-block fixation. Rev Inst Med Trop Sao Paulo. 2016;58:3.","journal-title":"Rev Inst Med Trop Sao Paulo"},{"key":"5100_CR16","doi-asserted-by":"publisher","first-page":"1443","DOI":"10.1590\/1678-4162-9053","volume":"69","author":"MP Campo","year":"2017","unstructured":"Campo MP, Madeira MF, Silva DA, Solc\u00e0 MS, Esp\u00edndola OM, Mendes Junior AAV, et al. Accuracy of quantitative polymerase chain reaction in samples of frozen and paraffin-embedded healthy skin for the diagnosis of canine visceral leishmaniasis. Arq Bras Med Vet Zootec. 2017;69:1443\u201350.","journal-title":"Arq Bras Med Vet Zootec."},{"key":"5100_CR17","unstructured":"LeishVet. Therapy for canine leishmaniosis. https:\/\/www.leishvet.org\/fact-sheet\/therapy\/. Accessed 16 Nov 2021."},{"key":"5100_CR18","doi-asserted-by":"publisher","first-page":"237","DOI":"10.1007\/978-1-61779-080-5_20","volume":"731","author":"J van Meerloo","year":"2011","unstructured":"van Meerloo J, Kaspers GJL, Cloos J. Cell sensitivity assays: the MTT assay. Methods Mol Biol. 2011;731:237\u201345.","journal-title":"Methods Mol Biol"},{"key":"5100_CR19","doi-asserted-by":"publisher","first-page":"1706","DOI":"10.1055\/s-0034-1383183","volume":"80","author":"M Donega","year":"2014","unstructured":"Donega M, Mello S, Moraes R, Jain S, Tekwani B, Cantrell C. Pharmacological activities of Cilantro\u02bcs aliphatic aldehydes against Leishmania donovani. Planta Med. 2014;80:1706\u201311.","journal-title":"Planta Med"},{"key":"5100_CR20","doi-asserted-by":"publisher","first-page":"1027","DOI":"10.1002\/j.1460-2075.1990.tb08206.x","volume":"9","author":"M Ouellette","year":"1990","unstructured":"Ouellette M, Fase-Fowler F, Borst P. The amplified H circle of methotrexate-resistant Leishmania tarentolae contains a novel P-glycoprotein gene. EMBO J. 1990;9:1027\u201333.","journal-title":"EMBO J"},{"key":"5100_CR21","doi-asserted-by":"crossref","first-page":"564","DOI":"10.4049\/jimmunol.135.1.564","volume":"135","author":"DL Sacks","year":"1985","unstructured":"Sacks DL, Hieny S, Sher A. Identification of cell surface carbohydrate and antigenic changes between noninfective and infective developmental stages of Leishmania major promastigotes. J Immunol. 1985;135:564\u20139.","journal-title":"J Immunol"},{"key":"5100_CR22","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1186\/s12864-016-2672-8","volume":"17","author":"PJ Alcolea","year":"2016","unstructured":"Alcolea PJ, Alonso A, Degay\u00f3n MA, Moreno-Paz M, Jim\u00e9nez M, Molina R, et al. In vitro infectivity and differential gene expression of Leishmania infantum metacyclic promastigotes: negative selection with peanut agglutinin in culture versus isolation from the stomodeal valve of Phlebotomus perniciosus. BMC Genomics. 2016;17:375\u201389.","journal-title":"BMC Genomics"},{"key":"5100_CR23","doi-asserted-by":"publisher","first-page":"617521","DOI":"10.1155\/2010\/617521","volume":"2010","author":"HC Maltezou","year":"2010","unstructured":"Maltezou HC. Drug resistance in visceral leishmaniasis. J Biomed Biotechnol. 2010;2010:617521.","journal-title":"J Biomed Biotechnol"},{"key":"5100_CR24","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1186\/1471-2210-2-11","volume":"2","author":"J Carri\u00f3","year":"2002","unstructured":"Carri\u00f3 J, Port\u00fas M. In vitro susceptibility to pentavalent antimony in Leishmania infantum strains is not modified during in vitro or in vivo passages but is modified after host treatment with meglumine antimoniate. BMC Pharmacol. 2002;2:11.","journal-title":"BMC Pharmacol"},{"key":"5100_CR25","doi-asserted-by":"publisher","first-page":"87","DOI":"10.1016\/j.vetpar.2019.05.006","volume":"271","author":"RC Giunchetti","year":"2019","unstructured":"Giunchetti RC, Silveira P, Resende LA, Leite JC, de Melo-J\u00fanior OAO, Rodrigues-Alves ML, et al. Canine visceral leishmaniasis biomarkers and their employment in vaccines. Vet Parasitol. 2019;271:87\u201397.","journal-title":"Vet Parasitol"},{"key":"5100_CR26","doi-asserted-by":"publisher","first-page":"16","DOI":"10.1016\/j.ijpddr.2020.04.004","volume":"13","author":"L van Bockstal","year":"2020","unstructured":"van Bockstal L, Bult\u00e9 D, Hendrickx S, Sadlova J, Volf P, Maes L, et al. Impact of clinically acquired miltefosine resistance by Leishmania infantum on mouse and sand fly infection. Int J Parasitol Drugs Drug Resist. 2020;13:16\u201321.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"5100_CR27","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1093\/jac\/dkx407","volume":"73","author":"A Mondelaers","year":"2018","unstructured":"Mondelaers A, Hendrickx S, van Bockstal L, Maes L, Caljon G. Miltefosine-resistant Leishmania infantum strains with an impaired MT\/ROS3 transporter complex retain amphotericin B susceptibility. J Antimicrob Chemother. 2018;73:392\u20134.","journal-title":"J Antimicrob Chemother"},{"key":"5100_CR28","doi-asserted-by":"publisher","first-page":"133","DOI":"10.1016\/j.ijpddr.2016.04.003","volume":"6","author":"V G\u00f3mez P\u00e9rez","year":"2016","unstructured":"G\u00f3mez P\u00e9rez V, Garc\u00eda-Hernandez R, Corpas-L\u00f3pez V, Tom\u00e1s AM, Mart\u00edn-Sanchez J, Castanys S, et al. Decreased antimony uptake and overexpression of genes of thiol metabolism are associated with drug resistance in a canine isolate of Leishmania infantum. Int J Parasitol Drugs Drug Resist. 2016;6:133\u20139.","journal-title":"Int J Parasitol Drugs Drug Resist"},{"key":"5100_CR29","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.exppara.2013.05.015","volume":"135","author":"C Maia","year":"2013","unstructured":"Maia C, Nunes M, Marques M, Henriques S, Rol\u00e3o N, Campino L. In vitro drug susceptibility of Leishmania infantum isolated from humans and dogs. Exp Parasitol. 2013;135:36\u201341.","journal-title":"Exp Parasitol"},{"key":"5100_CR30","unstructured":"Minist\u00e9rio da sa\u00fade (BR). Nota T\u00e9cnica No. 232\/2013. https:\/\/www.gov.br\/saude\/pt-br\/composicao\/conjur\/demandas-judiciais\/notas-tecnicas\/notas-tecnicas-medicamentos\/notas-tecnicas\/a\/anfotericina-b-atualizado-em-04-12-2015.pdf\/view. Accessed 18 Sep 2021."},{"key":"5100_CR31","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1186\/1471-2210-1-1","volume":"1","author":"SW Kamau","year":"2001","unstructured":"Kamau SW, Nunez R, Grimm F. Flow cytometry analysis of the effect of allopurinol and the dinitroaniline compound (Chloralin) on the viability and proliferation of Leishmania infantum promastigotes. BMC Pharmacol. 2001;1:1.","journal-title":"BMC Pharmacol"},{"key":"5100_CR32","doi-asserted-by":"publisher","first-page":"107947","DOI":"10.1016\/j.exppara.2020.107947","volume":"217","author":"\u00c1FLR Dias de","year":"2020","unstructured":"Dias de \u00c1FLR, Ayresda ECBS, de Oliveira Martins DT, Maruyama FH, de Oliveira RG, de Carvalho MR, et al. Comparative study of the use of miltefosine, miltefosine plus allopurinol, and allopurinol in dogs with visceral leishmaniasis. Exp Parasitol. 2020;217:107947.","journal-title":"Exp Parasitol"},{"key":"5100_CR33","doi-asserted-by":"publisher","first-page":"57","DOI":"10.1038\/s41467-017-00103-8","volume":"8","author":"JSP Doehl","year":"2017","unstructured":"Doehl JSP, Bright Z, Dey S, Davies H, Magson J, Brown N, et al. Skin parasite landscape determines host infectiousness in visceral leishmaniasis. Nat Commun. 2017;8:57.","journal-title":"Nat Commun"}],"container-title":["Parasites &amp; Vectors"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-021-05100-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s13071-021-05100-x\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s13071-021-05100-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,1,17]],"date-time":"2023-01-17T19:24:14Z","timestamp":1673983454000},"score":1,"resource":{"primary":{"URL":"https:\/\/parasitesandvectors.biomedcentral.com\/articles\/10.1186\/s13071-021-05100-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2021,12]]},"references-count":33,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2021,12]]}},"alternative-id":["5100"],"URL":"https:\/\/doi.org\/10.1186\/s13071-021-05100-x","relation":{},"ISSN":["1756-3305"],"issn-type":[{"value":"1756-3305","type":"electronic"}],"subject":[],"published":{"date-parts":[[2021,12]]},"assertion":[{"value":"11 August 2021","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"17 November 2021","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 December 2021","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The study was approved by the Ethics Committee on Animal Use of FIOCRUZ under protocol no. LW-14\/21.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"Not applicable.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare that they have no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"599"}}